Jefferies Financial Group Raises Eli Lilly and Company (NYSE:LLY) Price Target to $1,015.00

Eli Lilly and Company (NYSE:LLY) had its target price hoisted by Jefferies Financial Group from $994.00 to $1,015.00 in a research note issued to investors on Monday morning, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

Several other research firms have also recently commented on LLY. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a neutral rating in a report on Thursday, April 11th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an overweight rating in a report on Wednesday, May 1st. Truist Financial raised their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a buy rating in a report on Wednesday, May 1st. Finally, Argus increased their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a buy rating in a research report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of Moderate Buy and an average price target of $812.72.

Eli Lilly and Company Stock Down 0.4 %

Shares of LLY stock opened at $901.26 on Monday. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $909.42. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market cap of $856.57 billion, a PE ratio of 132.73, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36. The stock has a 50 day moving average of $804.54 and a 200-day moving average of $734.18.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the firm earned $1.62 EPS. The business’s revenue was up 26.0% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold 789,704 shares of company stock valued at $672,385,964 over the last three months. 0.13% of the stock is owned by insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Large investors have recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $5,992,890,000. International Assets Investment Management LLC lifted its stake in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares during the period. Swedbank AB bought a new position in Eli Lilly and Company during the first quarter worth about $932,797,000. Sapient Capital LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $682,139,000. Finally, Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after acquiring an additional 1,133,810 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.